References
- Hobbs MR, Jones BB, Otterud BE, Leppert M, Kriesel JD. Identification of a herpes simplex labialis susceptibility region on human chromosome 21. J Infect Dis. 2008;197:340–346.
- Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168:1137–1144.
- Beydoun HA, Dail J, Ugwu B, Boueiz A, Beydoun MA. Socio-demographic and behavioral correlates of herpes simplex virus type 1 and 2 infections and co-infections among adults in the USA. Int J Infect Dis. 2010;14:e154–e160; Epub;%2010 Apr 24.:e154-e160.
- Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J Infect Dis. 2000;181:1906–1910.
- Hull C, McKeough M, Sebastian K, Kriesel J, Spruance S. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol. 2009;23:263–267.
- Centers for Disease Control and Prevention. Survey instrument: national ambulatory medical care survey. http://www.cdc gov/nchs/about/major/ahcd/surinst. htm#Survey%20Instrument%20NAMCS.2007. Accessed August 16, 2012.
- Binns HJ, Lanier D, Pace WD, Galliher JM, Ganiats TG, Grey M, et al. Describing primary care encounters: the primary care network survey and the national ambulatory medical care survey. Ann Fam Med. 2007;5:39–47.
- Franks P, Clancy CM, Nutting PA. Defining primary care. Empirical analysis of the national ambulatory medical care survey. Med Care. 1997;35:655–668.
- U.S. Census Bureau. American FactFinder. U.S. Census Bureau. 2004. URL http://factfinder.census.gov/. Accessed July 30, 2012.
- Raborn GW, Grace MG. Recurrent herpes simplex labialis: selected therapeutic options. J Can Dent Assoc. 2003;69:498–503.
- Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–973.
- DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2010. www census gov/prod/2011pubs/p60-239 pdf.2011.
- Marks JG, Miller J. Lookingbill and Marks' principles of dermatology. 4th edition. Elsevier; Philadelphia, 2006.
- Usatine RP, Tinitigan R. Nongenital herpes simplex virus. Am Fam Physician. 2010;82:1075–1082.
- Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, Darpö B, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011;64:696–711.
- U.S. Food and Drug Administration. Drugs@FDA. http://www.accessdata.fda gov/scripts/cder/drugsatfda/index.cfm.2011. Accessed December 13, 2011.
- Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother. 2003;47:1072–1080.
- Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881–1884.